Axe Compute arrives at 2026 as a reborn company. What was Predictive Oncology - a money-losing maker of AI-driven tumor drug-response models - renamed itself Axe Compute in December 2025 and pivoted to reselling GPU compute for artificial intelligence workloads while parking much of its balance sheet in ATH, the native token of the Aethir decentralized GPU network. The quarter that closed March 31, 2026 is the first full look at the new shape of the business: a dollop of real compute revenue, a legacy drug-discovery operation being quietly shopped for sale, and a treasury whose token value swings the income statement far more than any operating line does.
The central tension is whether the pivot is a business or a speculation dressed as one. Q1 revenue was $35,311 - six-odd thousand dollars of it from GPU compute and most of the rest from the shrinking legacy unit - against a $7.7 million net loss that is itself flattered by treating a $4.3 million mark-to-market drop in ATH as an operating cost. The balance sheet at $45.2 million of assets is dominated not by machinery or contracts but by $20.2 million of digital assets and a $15.4 million receivable of ATH yet to vest. Management's answer to unit economics is one enormous contract signed just after the quarter closed: a 36-month, roughly $260 million enterprise agreement to deliver a dedicated cluster of over two thousand NVIDIA B300 GPUs.
So there are, plainly, two ways to read this stock. The first reads the pivot as a genuine transformation - a cash-poor oncology lab chose a token treasury and a resale model precisely so it could chase the GPU shortage with no data-center ownership, and then landed a landmark contract to prove it. The second reads the same facts as a shell that financed its second act by selling warrants for a discounted pile of a volatile token, with a contract whose $260 million headline still has to be delivered into real revenue that Q1 has yet to show. The price is a bet on the second-read failure mode being wrong. What decides the thesis between them is measurable: does the April contract deploy on time in the third quarter, does compute revenue begin to approximate the contract's run-rate, and does the ATH treasury keep its value - funding the build-out without destroying per-share value through dilution.